Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...
PALO ALTO, CA, USA I February 11, 2025 I BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused ...
EDA Explores Aircraft Battery Health Monitoring is published in Aerospace Daily & Defense Report, an Aviation Week ...
Achieving a digital transition that strengthens Europe's strategic competitiveness means addressing the persistent challenges in innovation, adoption, and technological dependency.